Download presentation
Presentation is loading. Please wait.
Published byRalf Fox Modified over 9 years ago
1
Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen I Pritchard Toronto-Sunnybrook Regional Cancer Centre and The University of Toronto Toronto, Canada
2
PROGNOSTIC FACTORS FACTORS WHICH PREDICT THE RISK OF RECURRENCE OR DEATH INDEPENDENT OF THERAPY
3
PREDICTIVE FACTORS FACTORS WHICH PREDICT THE LIKELIHOOD OF RESPONSE TO A GIVEN THERAPY
4
ESTROGEN RECEPTOR AND PROGESTERONE RECEPTOR BOTH PREDICTIVE AND PROGNOSTIC FACTORS
5
ESTROGEN RECEPTOR EXPRESSED IN 60-70% OF BREAST CANCERS A WEAK BUT FAVOURABLE PROGNOSTIC FACTOR
6
ESTROGEN AND PROGESTERONE RECEPTOR OBJECTIVE RESPONSE RATE
7
ESTROGEN RECEPTOR RESPONSE RATES INCREASE WITH INCREASING LEVELS OF ESTROGEN RECEPTOR PROTEIN WITLIFF 1988
8
ER AND PgR MEASUREMENT METHODS LIGAND BINDING OR BIOCHEMICAL DONE ON A “SLURRY” OF TISSUE YIELDS AN AVERAGE VALUE IMMUNOHISTOCHEMICAL DONE ON A SECTION CAN LOCALIZE RECEPTOR 1-10% OF CELLS STAINING STILL POSITIVE
9
COMPARISON OF ER AND/OR PgR IMMUNOHISTOCHEMICAL METHODS TO OLDER LIGAND BINDING OR BIOCHEMICAL METHODS EXCELLENT REVIEW BY CRAIG ALLRED et al MODERN PATHOLOGY 1998; 11 (2): 155-168 STRESSES VALIDATION OF NEW TEST METHODOLOGY WITH CLINICAL OUTCOME AS WELL AS WITH OLDER TEST METHODOLOGY
10
ESTROGEN RECEPTOR IHC PREPARATION OF TISSUE TYPES OF ANTIBODIES ARBITRARY SCORING INTERPRETATION REPORTING
11
ESTROGEN RECEPTOR LB=LIGAND ASSAY BINDING IHC=IMMUNOHISTOCHEMICAL IHC and LB 80-90% CONCORDANT
12
ESTROGEN RECEPTOR PROGNOSTIC VALUE OF ER BY IHC ~ 10-15% RECURRENCE/SURVIVAL BENEFIT IN WOMEN WHO DO NOT RECEIVE HORMONAL ADJUVANT THERAPY CONFIRMED IN AT LEAST FOUR TRIALS INVOLVING UNTREATED WOMEN
13
DISEASE FREE SURVIVAL OF WOMEN RECEIVING HORMONAL THERAPY
15
ESTROGEN RECEPTOR PREDICTIVE VALUE OF ER BY IHC 20 STUDIES 1200 WOMEN ER +ve ~ 70% RR ER -ve< 15% RR
16
PROGESTERONE RECEPTOR PG-R AN ER-RELATED GENE PRODUCT INDICATES WHETHER THE ESTROGEN / E.R. REGULATED PATHWAYS ARE INTACT
17
PROGESTERONE RECEPTOR LB vs IHC ~ 70% CONCORDANCE IHCRR PgR +ve70% PgR-ve < 10%
18
PROGESTERONE RECEPTOR IHC TISSUE PREPARATION TYPES OF ANTIBODIES SCORING INTERPRETATION REPORTING
19
PROGESTERONE RECEPTOR WEAK PROGNOSTIC FACTOR ~ 5% DIFFERENCE IN 713 UNTREATED WOMEN
20
DISEASE FREE SURVIVAL OF WOMEN RECEIVING HORMONAL THERAPY
22
PREDICTIVE VALUE OF RECEPTORS PHENOTYPE INCIDENCE RESPONSE RATE ER + PgR+58%77% ER + PgR-23%27% ER - PgR+ 4%46% ER - PgR-15%11% McGuire 1991
23
ESTROGEN RECEPTOR PREDICTIVE VALUE FOR CHEMOTHERAPY PROPOSED AS A PREDICTIVE FACTOR FOR CHEMOTHERAPY RESPONSE ER -ve MORE LIKELY TO RESPOND TO CHEMO LIPPMAN ET AL NEJM 1978
24
ESTROGEN RECEPTOR PREDICTIVE VALUE FOR CHEMOTHERAPY SUBSEQUENTLY REJECTED AS A PREDICTIVE FACTOR BASED ON CONTRADICTORY DATA FROM A SERIES OF SMALL STUDIES IN METASTATIC DISEASE
25
ESTROGEN RECEPTOR AC vs AC T DIFFERENCE MAINLY IN ER -ve LITTLE DIFFERENCE IN ER +ve HENDERSON ET AL ASCO 2000
26
ESTROGEN RECEPTOR OXFORD OVERVIEW SUGGESTION IN SOME ANALYSES THAT WOMEN WITH ER NEGATIVE TUMOURS BENEFIT MORE FROM CHEMOTHERAPY COLE, LANCET 2001 COATES, LANCET 1998
27
ESTROGEN RECEPTOR MECHANISMS BREAST CANCER DEVELOPMENT AND PROGRESSION DIRECTLY RELATED TO EFFECTS OF ESTROGEN ER A NUCLEAR RECEPTOR FUNCTIONS AS A TRANSCRIPTION FACTOR CONTROLLING ESTROGEN RELATED GENES
28
ESTROGEN RECEPTOR MECHANISMS LIGAND BINDING RECEPTOR CONFORMATION INTERACTION OF RECONFORMED RECEPTOR WITH COREGULATORS RESPONSE ELEMENTS IN PROMOTOR REGIONS OF TARGET GENES (ERE) ALL CONTRIBUTES TO NET ESTROGENIC EFFECTS IN A CELL
29
ESTROGEN RECEPTOR MECHANISMS POLYPEPTIDE GROWTH FACTORS AND THEIR MEMBRANE RECEPTORS ALSO CONTRIBUTE TO BREAST CANCER DEVELOPMENT AND PROGRESSION SIGNALS THROUGH VARIOUS PROTEIN KINASE PATHWAYS ENHANCE CELL SURVIVAL AND PROLIFERATION
30
ESTROGEN RECEPTOR MECHANISMS THESE PATHWAYS ALSO INTERACT WITH ESTROGEN RECEPTOR KINASES IN GROWTH FACTOR CASCADE CAN PHOSPHORYLATE AND ACTIVATE ER ER IN TURN ACTIVATES AND AUGMENTS SIGNALING IN GROWTH FACTOR PATHWAYS
31
ESTROGEN RECEPTOR MECHANISMS SIGNALING THROUGH GF PATHWAYS MAY CONTRIBUTE TO HORMONAL RESISTANT STATES BY LIGAND - INDEPENDENT ACTIVATION OF ER THUS TARGETING GF PATHWAYS IN ADDITION TO ER MAY PROVIDE BETTER THERAPY
32
ESTROGEN RECEPTOR MECHANISMS CLASSIC HORMONAL THERAPIES BIOLOGIC AGENTS ANTI HER-2 HERCEPTIN OTHERS ANTI EGF IRESSA OTHERS
33
PREDICTIVE MOLECULAR MARKERS: HORMONE RECEPTOR STATUS CONCLUSIONS STILL CRUCIAL IN SELECTION OF HORMONAL THERAPY MEASUREMENTS MUST BE STANDARDIZED TISSUE PREPARATON ANTIBODY USED SCORING INTERPRETATION REPORTING
34
PREDICTIVE MOLECULAR MARKERS: HORMONE RECEPTOR STATUS QUESTIONS ? ER / PgR ROLE IN SELECTING CHEMOTHERAPY ? Her 2 - Neu ROLE IN SELECTING CHEMOTHERAPY ROLE IN SELECTING HORMONAL THERAPY ? EGF - R (Erb - B1) ROLE IN SELECTING THERAPY
35
PREDICTIVE MOLECULAR MARKERS: HORMONE RECEPTOR STATUS QUESTIONS ? OPTIMAL USE OF COMBINATIONS OF CLASSIC HORMONAL AND BIOLOGIC FACTORS ? OPTIMAL GUIDANCE OF THIS COMBINED THERAPY BY CAREFUL STANDARDIZATION OF LABORATORY MEASUREMENTS
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.